Pancreatic cancer has long been one of the most difficult cancers to treat. For decades, patients and doctors have faced a harsh reality.
The disease is often discovered late, after it has already spread to other parts of the body, and treatment options have been limited.
Survival rates remain much lower than those for many other common cancers. Because of this, researchers around the world have been searching for new ways to fight the disease.
Now, a new study offers hope that meaningful progress may finally be happening.
Researchers reported that an experimental pill called daraxonrasib helped people with advanced pancreatic cancer live significantly longer than standard chemotherapy after previous treatments had stopped working.
The findings were published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology meeting in Chicago.
Pancreatic cancer begins in the pancreas, an organ located behind the stomach that helps the body digest food and control blood sugar levels.
One reason the disease is so deadly is that it often causes few symptoms in its early stages. By the time it is diagnosed, the cancer has frequently spread beyond the pancreas, making it much harder to treat successfully.
According to the American Cancer Society, around 67,000 people in the United States are expected to be diagnosed with pancreatic cancer this year, and more than 52,000 are expected to die from it. The overall five-year survival rate is only about 13 percent. These numbers show why doctors are eager for better treatment options.
The new drug focuses on a genetic problem that is found in more than 90 percent of pancreatic cancers. Many tumors contain mutations in a gene called KRAS, which helps control how cells grow and divide. When KRAS becomes mutated, it can continuously send growth signals that encourage cancer cells to multiply uncontrollably.
For many years, scientists considered KRAS to be nearly impossible to target with drugs. Researchers often referred to it as “undruggable” because its structure made it difficult for medicines to attach to it. This challenge frustrated cancer researchers for decades.
Daraxonrasib appears to overcome that obstacle. The drug acts like a molecular glue that attaches to several forms of mutated KRAS proteins and blocks their activity. By shutting down this important cancer-driving signal, the drug can slow tumor growth and, in some cases, shrink tumors.
The study involved approximately 500 patients whose metastatic pancreatic cancer had already stopped responding to earlier treatments. Participants were randomly assigned to receive either daraxonrasib or additional chemotherapy. This type of study design helps researchers make fair comparisons between treatments.
The results surprised many cancer specialists. Patients taking daraxonrasib lived a median of 13.2 months, compared with 6.7 months for those receiving chemotherapy. In other words, survival time was nearly doubled.
While an increase of several months may not sound dramatic to some people, cancer specialists say it is a major achievement in pancreatic cancer research. For a disease that has seen relatively few breakthroughs, this level of improvement is considered highly significant.
Researchers also found that patients receiving the pill generally experienced a better quality of life. Many reported less pain, and their tumors often shrank during treatment. Patients remained on the drug much longer than those receiving chemotherapy, suggesting that the treatment continued providing benefits over time.
Like all cancer treatments, the drug has side effects. The most common problems included skin rashes and mouth sores. However, researchers reported fewer severe side effects compared with chemotherapy.
Experts not involved in the study expressed excitement about the findings. Several specialists described the results as a potential turning point in pancreatic cancer treatment. They believe the drug may soon become a standard treatment for patients whose cancer has progressed after earlier therapies.
Researchers are now exploring whether the drug could help patients earlier in the disease process. If tumors can be shrunk before surgery, more patients may become eligible for operations that could potentially extend survival even further.
The U.S. Food and Drug Administration is expected to review the treatment through an accelerated process. Meanwhile, some eligible patients are already receiving access through special expanded-access programs.
The study provides strong evidence that targeting KRAS can produce meaningful benefits for patients with advanced pancreatic cancer. However, it is important to recognize the limitations. The drug is not a cure, and the cancer eventually continues to progress in many patients.
Researchers will need to follow patients for longer periods to determine how durable the benefits are. In addition, the study was funded by the company developing the drug, making independent confirmation important.
Even with these limitations, the results represent one of the most encouraging developments seen in pancreatic cancer treatment in many years.
The nearly doubled survival time, improved quality of life, and manageable side effects suggest that daraxonrasib could become an important new tool against a disease that has long resisted medical progress.
If you care about cancer, please read studies about how to fight cancer with these anti-cancer superfoods ,and a berry that can prevent cancer, diabetes and obesity.
For more health information, please see recent studies about how to harness the power of anti-cancer foods and supplements, and cancer-fighting foods and recipes.
